Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 2/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350639 | 0.82 | CSF1R (0.47) | ANO1 | |
| SCHEMBL6415714 | 0.82 | MAOB (0.53) | ANO1CNR2 | |
| SCHEMBL6419679 | 0.81 | ANO1 (0.47) | ANO1CNR2 | |
| SCHEMBL13388549 | 0.81 | ALDH1A1 (0.55) | ANO1CNR2 | |
| SCHEMBL29503927 | 0.81 | ANO1 (0.47) | ANO1CNR2 | |
| SCHEMBL19164278 | 0.81 | ANO1 (0.44) | DEGS1ANO1CNR2 | |
| SCHEMBL2645831 | 0.79 | USP7 (0.50) | DEGS1 | |
| SCHEMBL1020382 | 0.79 | P4HTM (0.59) | — | |
| SCHEMBL3485307 | 0.78 | CNR2 (0.43) | DEGS1CNR2 | |
| SCHEMBL26772954 | 0.78 | NPC1 (0.48) | DEGS1ANO1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | DEGS1 4339/4885ANO1 4461/4885CNR2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.